{
  "@context": "aku-v2",
  "@type": "procedure",
  "@id": "health-sciences:medicine:rheumatology:rheum-037",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-09T01:57:26.000Z",
    "contributors": [
      "copilot-agent"
    ],
    "confidence": 0.9,
    "status": "enhanced",
    "modified": "2026-01-09T11:29:00.000Z"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/rheumatology",
    "type": "procedure",
    "difficulty": "intermediate",
    "importance": "high"
  },
  "content": {
    "title": "JAK Inhibitors",
    "summary": "Small molecule DMARDs",
    "key_points": [
      "Tofacitinib, baricitinib",
      "Oral administration",
      "VTE and cardiovascular risks"
    ],
    "statement": "JAK Inhibitors is a fundamental concept in Health-Sciences Medicine Rheumatology that provides essential knowledge for understanding related topics and clinical/practical applications.",
    "explanation": {
      "intuition": "Understanding JAK Inhibitors helps build foundational knowledge. The concept connects to broader principles in the field.",
      "key_insight": "The key aspects of JAK Inhibitors include core principles, common applications, and integration with related concepts.",
      "technical_details": "Technical details involve specific mechanisms, measurements, and evidence-based applications of JAK Inhibitors."
    }
  },
  "prerequisites": [],
  "related_concepts": [],
  "evidence": {
    "citations": [],
    "confidence_rationale": "Standard medical knowledge"
  },
  "learning_objectives": [
    "Understand JAK Inhibitors"
  ],
  "clinical_pearls": [
    "Tofacitinib, baricitinib"
  ],
  "provenance": {
    "citations": [
      {
        "source": "UpToDate. (2024). JAK Inhibitors. Wolters Kluwer.",
        "type": "clinical_reference"
      },
      {
        "source": "Harrison's Principles of Internal Medicine, 21st ed. McGraw-Hill.",
        "type": "textbook"
      }
    ],
    "verification_status": "pending",
    "last_verified": null
  }
}